1 / 45

Glycopeptides, Oxazolidinones, Streptogramins and Aminoglycosides

Glycopeptides, Oxazolidinones, Streptogramins and Aminoglycosides. Hail M. Al-Abdely, MD Consultant, Adult Infectious Diseases King Faisal Specialist Hospital and Research Center. AIM OF THIS PRESENTATION. Practical use of these antibiotics. No sophisticated stuff!!.

ellery
Download Presentation

Glycopeptides, Oxazolidinones, Streptogramins and Aminoglycosides

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Glycopeptides, Oxazolidinones, Streptogramins and Aminoglycosides Hail M. Al-Abdely, MD Consultant, Adult Infectious Diseases King Faisal Specialist Hospital and Research Center

  2. AIM OF THIS PRESENTATION Practical use of these antibiotics No sophisticated stuff!!

  3. Driving forces behind Drug development • Good market • Common NOT rare (pseudomonas versus Burkhelderia) • Common in the rich (HIV versus leishmania) • Difficult to treat • Emerging new organisms (Fungi in immune suppressed patients) • Resistance in old organisms (several bacteria) • Better kinetics and safety (Ampho B versus Azoles) • Basic Human need

  4. Glycopeptides

  5. Glycopeptides • Vancomycin • Licensed throughout the world • Teicoplanin • Not FDA approved

  6. Vancomycin • Vancomycin is obtained from Nocardia orientalis • Vancomycin has been used clinically since 1956 • Recent improvements in manufacturing have increased its purity and reduced its toxicity • Pure gram positive spectrum

  7. Vancomycin • Vancomycin is bactericidal (except enterococcus) • binds to the precursor units of bacterial cell walls (peptidoglycans), inhibiting their synthesis. • In addition, RNA synthesis is inhibited • Work systemically, topically and locally • Systemic gram-positive infections • C. difficile colitis • Shunt infections/ventriculitis

  8. When do you need Vancomycin Nafcillin Vancomycin

  9. When do you need Vancomycin • Resistance to better drugs • MRSA, Coagulase-negative Staphylococi • Amp-resistant enterococcus, • Some corynebacteria and bacillus • Allergy to better drugs • Toxicity of better drugs • Empiric therapy for suspected resistance • Special situations • Dosing intervals in OPD setting • Dialysis

  10. Disadvantages of Vancomycin • Parentral • Poor penetration to CSF • Lower efficacy than penicillins • Mild to moderate toxicity • Resistance • VRSA • VRE

  11. Nosocomial Enterococci Reported as Resistant to Vancomycin, by Year *National Nosocomial Infections Surveillance (NNIS) System Data, 1989-1999.

  12. Vancomycin-resistant enterococci Non-Intensive Care Unit Patients Intensive Care Unit Patients Source: National Nosocomial Infections Surveillance (NNIS) System

  13. Due you need to measure levels • No except • Pre-existing renal impairment • Rising creatinine • Co-administered nephrotoxic drugs • Assure therapeutic levels (serious infections) • Measure only trough levels (pre-dose) • Dialysis patients: pre-dialysis level • STOP weekly vancomycin dosing in HD patients

  14. Teicoplanin • Similar to vancomycin in spectrum • Once daily and I.M dosing • May retain activity against vancomycin-resistant Staphylococcus aureus • More active against enterococcus than vancomycin

  15. When you may need Teicoplanin • Dosing advantages for out-patient treatment • VRSA • Some strains of VRE

  16. Lipopepetides

  17. Daptomycin

  18. Lipopepetides • Daptomycin • Approval by FDA September 2003 for treatment of complicated skin and soft tissue infections • Mechanism of action: disruption of the plasma membrane function. • Bacteriocidal against multidrug-resistant, gram-positive bacteria • Methicillin-resistant Staphylococcus aureus • Vancomycin-resistant enterococci • Glycopeptide-intermediate and -resistant S. aureus. • Penicillin-resistant Streptococcus pneumoniae

  19. Daptomycin • Fast bacteriocidal action • Concentration-dependent killing • Post antibiotic effect • Once daily dosing • Excreted mainly through kidneys

  20. Streptogramins

  21. quinupristin dalfopristin

  22. Streptogramins • Isolated from Streptomyces pristinaespiralis • Used as oral agents in France since the 1960s • Dalfopristin and quinupristin are the only parentral agents • The combination product (Synercid®) has up to 16 times the activity of each agent alone • Streptogramins inhibit bacterial protein synthesis by irreversibly blocking ribosome functioning • Each component is bacteriostatic but the combination is bacteriocidal • The main reason for development and approval is VRE

  23. Synercid™ • Combination of dalfopristin and quinupristin • administered by intravenous infusion • Metabolism is not dependent on cytochrome P450. But a major inhibitor of the activity of cytochrome P450 3A4 isoenzyme • Elimination through fecal excretion

  24. When you may ask for Synercid™ • Serious VRE infection • MRSA infection for which you can not use vancomycin +/- linezolid

  25. Safety of Synercid™ • Safe with no major toxicities • Thrombophlebitis, GI • Mostly given through a CVL

  26. Oxazolidinones

  27. Oxazolidinones • Synthetic antibiotics • One approved (Linezolid), some are still investigational (Eperezolid, furazolidone)

  28. Linezolid

  29. Linezolid • Approved for use in adults April 2000 and for pediatrics December 2002 • Works against aerobic gram-positive organisms • Linezolid inhibits bacterial protein synthesis by interfering with translation • binds to a site on the bacterial 23S ribosomal RNA of the 50S subunit; this action prevents the formation of a functional 70S initiation complex, an essential step in the bacterial translation process

  30. Linezolid • Linezolid is administered by intravenous infusion or orally • oral bioavailability for linezolid is 100%. • have significant penetration into bone, fat, muscle, and hematoma fluid • metabolism is non-enzymatic and does not involve CYP450 • does not inhibit or induce CYP450 isoenzymes. • Non-renal clearance accounts for 65% of an administered linezolid dosage (no adjustment in renal failure)

  31. Indications of Linezolid • Mainly developed because of VRE • first new antibiotic approved to target methicillin-resistant staphylococci in 35 years

  32. Resistance to Linezolid • linezolid-resistant VRE organisms were being discovered in various institutions • Also some MRSA

  33. Safety of Linezolid • linezolid is a non-selective inhibitor of monoamine oxidase (MAO)

  34. AMINOGLYCOSIDES

  35. AMINOGLYCOSIDES Members of the Group Streptomycin Dibekacin Neomycin Netilmicin Kanamycin Sisomycin Gentamycin Aminosidine Tobramycin Paromomycin Amikacin Spectinomycin Arbikacin

  36. AMINOGLYCOSIDES • Mechanism of Action • interfere with protein synthesis • active transport mechanism • Mode of Action • bactericidal

  37. AMINOGLYCOSIDES • Antibacterial activity • Spectrum: • aerobic gram (-) bacteria • mycobacteria • Brucella • gram (+) bacteria • Characteristics • Highly polar cations  limited distribution • Low activity in low PH

  38. AMINOGLYCOSIDES • Pharmacodynamics • Concentration dependent killing • Postantibiotic effect • Once daily dosing • Similar efficacy • Low nephrotoxicity

  39. AMINOGLYCOSIDES Pharmacokinetics Absorption very poorly absorbed parenteral Distribution negligible binding to plasma proteins excluded from most cells VD = ECF in renal cortex / inner ear Excretion GF

  40. AMINOGLYCOSIDES Mechanisms of Resistance • inactivation by microbial enzymes • Plasmid-mediated • Acetylases, adnylases, phosphorylases • Amikacin is the most stable • impaired intracellular transport / failure of permeation • altered ribosomal binding site / low affinity of the drug • Enterococcus: In cases of high level resistance to gentamicin, you can only use streptomycin

  41. PROBLEMS OF AMINOGLYCOSIDES • Adverse Effects • Ototoxicity • Nephrotoxicity  Monitoring • Neurotoxicity • Distribution  Combined with other agents • Resistance  Alternatives

  42. Monitoring levels of Aminoglycosides • Trough levels correlate with nephrotoxicity and a lesser extent ototoxicity • High peak levels in elderly can be associated with nephrotoxicity and ototoxicity • If dosing once daily, check trough levels. They should be non-detectable • Close monitoring is essential in renal impairment

  43. Final Statement • Microbes are going to stay with us no mater what we do to them • Those who are going to stay with us are those that are most resilient (i.e. resistant) ones that can adapt to all of our weapons • So, let’s try to keep facing the less resilient ones; those that we can treat effectively • We do that by a “wise” management of the battle with microbes through judicious use of antimicrobials.

  44. Thank you

More Related